Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who
 have lost a satisfactory response to adalimumab.
Inclusion Criteria:

 -  Moderate to severe plaque psoriasis

 -  Loss of satisfactory response to adalimumab

 -  Currently receiving or recently discontinued treatment with adalimumab

 Exclusion Criteria:

 -  Active skin conditions that would interfere with evaluations of the effect of
 investigational product on psoriasis

 -  Serious medical conditions